Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?

Batista, Marta Vaz; Pérez-Gracia, José Luis; Eiriz, Inês; Gión, María; Llombart-Cussac, Antonio; Cortés, Javier

doi:10.18632/oncotarget.28435

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of monoclonal antibodies dramatically changed the treatment approaches of patients with HER2-positive BC. 11 , 25 Promising results of anti-HER2 therapies prompted further investigation of their efficacy in patients with BM. 11 , 25 The HER2CLIMB was the first randomized CT to include heavily pretreated patients with active BMs.…”

Section: Discussionmentioning

confidence: 99%

“… 11 , 25 Promising results of anti-HER2 therapies prompted further investigation of their efficacy in patients with BM. 11 , 25 The HER2CLIMB was the first randomized CT to include heavily pretreated patients with active BMs. 26 The study evaluated the combination of tucatinib, an oral tyrosine kinase inhibitor, with trastuzumab and capecitabine in 198 patients with metastatic BC compared with placebo plus trastuzumab and capecitabine in 93 patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation